Find Paid Clinical Trials in Maryland

Paid Clinical Trials and Focus Groups by Location

All Locations ... United States » ... Maryland

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol dose A; Drug: Indacaterol dose B; Drug: Indacaterol dose C; Drug: Indacaterol dose D; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology

Conditions: HIV; Cardiovascular Disease
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Management Practices and the Risk of Infection Following Cardiac Surgery

Conditions: Cardiac Surgery; Infection, Postoperative Wound; Postoperative Wound Infection; Infections, Nosocomial; Management Practices
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis(ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Placebo; Drug: 250 mg CK-2017357; Drug: 500 mg CK-2017357
Sponsor: Cytokinetics
Recruiting - verified March 2010
Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

Condition: Healthy
Intervention: Drug: SRX246
Sponsor: Azevan Pharmaceuticals
Not yet recruiting - verified March 2010
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

Condition: Stem Cell Transplantation
Interventions: Biological: Auto-hMSCs; Biological: Allo-hMSCs
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); University of Miami
Not yet recruiting - verified October 2009
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Condition: B Cell Malignancies
Intervention: Genetic: Anti-CD19-CAR-transduced T cells
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Top-Down Attentional Control of Visual-Processing

Conditions: Focal Brain Lesion; Focal Lesions; fMRI
Intervention:
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified November 2009
Whole Genome Medical Sequencing for Genome Discovery

Conditions: Multiple Congenital Anomaly Syndromes; Congenital Disorders; Inherited Diseases
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified January 2010
Mothers' Thoughts About What Their Children Eat

Condition: Healthy Volunteers
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2010
Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment

Conditions: Hairy Cell Leukemia (HCL); Chronic Lymphocytic Leukemia (CLL); Non-Hodgkins Lymphoma (NHL); Cutaneous T Cell Lymphoma (CTCL); Adult T Cell Lymphoma (ATL)
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy

Conditions: Cerebral Palsy; Children; Adolescents
Intervention: Behavioral: Physical Exercise
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2010
Rituximab for Autoimmune Retinopathy

Condition: Autoimmune Disease
Intervention: Drug: Rituximab
Sponsor: National Eye Institute (NEI)
Recruiting - verified October 2009
Heart Biomarker Evaluation in Apnea Treatment

Conditions: Cardiovascular Disease; Obstructive Sleep Apnea; Coronary Artery Disease
Interventions: Other: Healthy Lifestyles and Sleep Education plus PAP; Other: Healthy Lifestyles and Sleep Education plus Supplemental Oxygen; Other: Healthy Lifestyles and Sleep Education
Sponsors: University Hospitals of Cleveland; Case Western Reserve University; Partners HealthCare; Johns Hopkins University; VA Boston Healthcare System
Recruiting - verified March 2010
A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Non-Hodgkin's Lymphoma (NHL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL)
Intervention: Drug: CAT-8015
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Study to Investigate CAL-101 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine
Sponsor: Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Condition: Influenza A Virus, H5N1 Subtype
Interventions: Biological: VRC-AVIDNA036-00-VP; Biological: Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

Condition: Coronary Artery Disease
Intervention: Drug: Omacor, omega-3 fatty acids in CAD patients
Sponsors: HeartDrug Research LLC; University of Oslo
Not yet recruiting - verified March 2010
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2010
Peripartum Cardiomyopathy

Condition: Pregnant Women With Peripartum Cardiomyopathy
Intervention:
Sponsors: University of Pittsburgh; National Institutes of Health (NIH)
Recruiting - verified March 2010
Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Testosterone; Drug: Etoposide
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified March 2010
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

Condition: Dengue Virus
Interventions: Biological: Investigational Vaccine for DEN1; Other: Placebo injection
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

Conditions: Peanut Hypersensitivity; Food Hypersensitivity; Immediate Hypersensitivity
Interventions: Drug: Peanut powder; Drug: Peanut extract; Drug: Placebo extract; Drug: Placebo powder
Sponsor: Johns Hopkins University
Recruiting - verified March 2010
Rivastigmine Study in Adolescents With Down Syndrome

Condition: Down Syndrome
Interventions: Drug: Rivastigmine; Other: Liquid Placebo
Sponsors: Duke University; Taishoff Family Foundation
Recruiting - verified March 2010
Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

Conditions: Obesity; Bariatric Surgery; Morbid Obesity; Diabetes Mellitus Type 2; Diet Therapy
Interventions: Procedure: Roux-en-Y Gastric Bypass; Behavioral: Caloric Restriction
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis

Condition: Lupus Nephritis
Interventions: Drug: laquinimod 0.5mg + standard of care; Drug: laquinimod 1mg + standard of care; Other: placebo + standard of care
Sponsor: Teva Pharmaceutical Industries
Not yet recruiting - verified March 2010
Vertos Mild® Patient Outcomes 02

Condition: Lumbar Spinal Stenosis
Intervention: Device: Minimally Invasive Lumbar Decompression (Mild®)
Sponsor: Vertos Medical, Inc.
Recruiting - verified March 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicines.

Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Efficacy and Safety of Different Doses of Indacaterol

Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA); National Institutes of Health (NIH)
Not yet recruiting - verified March 2010
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Stand Up To Cancer; Genentech; Abraxis BioScience Inc.
Not yet recruiting - verified March 2010
A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine

Condition: Pancreatic Cancer
Intervention: Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified March 2010
The Molecular Anatomy of Oral Wound Healing

Conditions: Wounds and Injuries; Wound Healing; Ulcer
Intervention:
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2009
Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness

Conditions: Cancer; Pain
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified August 2009
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

Condition: Diabetic Macular Edema
Interventions: Drug: Ranibizumab; Drug: ranibizumab
Sponsors: Johns Hopkins University; Juvenile Diabetes Research Foundation
Recruiting - verified February 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Left Ventricular Structural Predictors of Sudden Cardiac Death

Conditions: Ischemic Cardiomyopathy; Nonischemic Cardiomyopathy
Intervention:
Sponsors: Johns Hopkins University; Donald W. Reynolds Foundation; Christiana Care Health Services
Recruiting - verified February 2010
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites

Condition: Malignant Ascites
Interventions: Procedure: paracentesis; Device: pleurx catheter
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified February 2010
nEw3 Post-approval Study

Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
4968 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
4965 Post-approval Study

Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

Condition: Bowel Preparation
Interventions: Drug: PicoPrep; Drug: HalfLytely
Sponsor: Ferring Pharmaceuticals
Not yet recruiting - verified February 2010
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy

Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391
Sponsor: Kinex Pharmaceuticals, LLC
Recruiting - verified March 2010
Evaluation of the Safety and Immune Response of Two Admixtures of a Tetravalent Dengue Virus Vaccine

Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine-Admixture 1; Biological: TetraVax-DV Vaccine-Admixture 2; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health
Not yet recruiting - verified February 2010
12-week Efficacy of Indacaterol

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products

Conditions: Bone Marrow; Bone Marrow Stromal Cells; Mesenchymal Stem Cells; Blood Donors
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2010
Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis

Conditions: Cannabis Use; Drug Abuse
Intervention: Drug: Cannabis Cigarette
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2009
GDC-0449 and RO4929097 in Treating Women With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: ASP1941; Drug: Metformin; Drug: Placebo
Sponsor: Astellas Pharma Inc
Recruiting - verified March 2010
The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait

Condition: Parkinson Disease
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified December 2009
A Dose-escalation Study in Subjects With Advanced Malignancies

Condition: Advanced Malignancies
Intervention: Drug: INCB028060
Sponsors: Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified February 2010
Athena Pelvic Muscle Trainer - DUETS Trial

Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

Condition: Influenza
Interventions: Drug: Favipiravir; Drug: Favipiravir; Drug: Placebo comparator
Sponsor: Toyama Chemical Co., Ltd.
Recruiting - verified March 2010
A 6 Month Study of Once Daily Ciclesonide HFA Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Condition: Perennial Allergic Rhinitis
Intervention: Drug: ciclesonide HFA 160 μg
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

Conditions: Hypertension, Pulmonary; Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Not yet recruiting - verified March 2010
A Study in Patients With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
New Techniques to Evaluate Mitral Regurgitation

Condition: Mitral Valve Regurgitation
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2009
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

Conditions: Chronic Granulomatous Disease (CGD); Atherosclerosis; Immune Deficiencies; Inflammatory Bowel Disease
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
Imaging Cannabinoid CB1 Receptors in Schizophrenia

Condition: Schizophrenia
Intervention:
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified January 2010
Simvastatin Therapy for Moderate and Severe COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: simvastatin; Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Ezatiostat Hydrochloride; Drug: Lenalidomide (Revlimid®)
Sponsor: Telik
Recruiting - verified February 2010
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin; Drug: Rituximab; Drug: Bendamustine
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
Cardiac MRI for Patients Enrolled in INFUSE-AMI

Conditions: Acute Myocardial Infarction; Coronary Artery Disease; Myocardial Fibrosis; Gadolinium; Myocardial Edema
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2009
Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers

Condition: Anxiety Disorders
Intervention:
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified December 2009
Exome Sequencing in Autistic Spectrum Disorder

Condition: Autism Spectrum Disorder
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2009
SPIROCOR Coronary Outcome by Respiratory Stress Examination

Condition: Severe Coronary Artery Disease (S-CAD)
Intervention:
Sponsor: Spirocor
Recruiting - verified March 2010
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Conditions: Non-small Cell Lung Cancer; Adenocarcinoma
Interventions: Drug: SS1 (dsFv) PE38; Drug: Paclitaxel; Drug: Carboplatin; Drug: Bevacizumab
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2009
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Conditions: Neoplasms; Lymphoma
Interventions: Drug: LMP 400; Drug: LMP 776
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: Placebo; Drug: FF Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Ixabepilone + Carboplatin Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Chronic Obstructive Pulmonary Disease
Interventions: Drug: FF Inhalation Powder; Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Preventative Misconception Intervention

Conditions: HIV; HIV Infections
Interventions: Behavioral: 1-sided messages; Behavioral: 2-sided messages
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified February 2010
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified March 2010
Miltefosine to Treat Mucocutaneous Leishmaniasis

Conditions: Mucosal Leishmaniasis; Cutaneous Leishmaniasis
Intervention: Drug: miltefosine
Sponsor: Paladin Labs (USA) Inc.
Not yet recruiting - verified March 2010
A Study for Patients With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN5401; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified February 2010
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Condition: Partial Epilepsy
Intervention: Drug: VX-765
Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting - verified February 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macula Edema

Condition: Diabetic Macular Edema
Intervention: Biological: MP0112
Sponsor: Molecular Partners AG
Recruiting - verified March 2010
A Study is to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered Tapentadol ER at Dosages of 100 to 250 mg Twice Daily Compared With Placebo in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified February 2010
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Condition: Familial Amyotrophic Lateral Sclerosis
Intervention: Drug: ISIS 333611
Sponsors: Isis Pharmaceuticals; Muscular Dystrophy Association; ALS Association
Recruiting - verified February 2010
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
Sponsor: Pfizer
Recruiting - verified March 2010
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Condition: Alzheimer Disease
Interventions: Drug: galantamine; Drug: galantamine; Drug: BMS-708163
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Drug-Drug Interaction Study With Aricept® (Donepezil)

Condition: Alzheimer Disease
Interventions: Drug: Donepezil; Drug: BMS-708163
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Measuring Distress Tolerance With Functional MRI

Condition: Cocaine Dependence
Intervention:
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse and University of Maryland, College Park, MD
Recruiting - verified December 2009
Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study.

Condition: Movement Disorder
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2009
Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

Conditions: Cannabis; Dependence; Cannabis Abuse; Pharmacokinetics; fMRI
Interventions: Drug: Sativex(Registered Trademark); Drug: THC
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2009
Dopamine Function and Reward Processing In Schizophrenia

Condition: Schizophrenia
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2009
Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI

Conditions: Nicotine Dependence; Drug Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2009
Effects of Nicotine on Brain Activity as Measured by fMRI

Conditions: Nicotine Dependence; Drug Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2009
Screening Protocol for the Evaluation of Research Participants

Conditions: Substance Abuse; Disorders
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2010
The Effects of Expectation on Natural and Drug -Induced Rewards

Condition: Drug Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified June 2009
A Study in Semagacestat for Alzheimer's Patients

Condition: Alzheimer's Disease
Intervention: Drug: Semagacestat
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction

Condition: Nicotine Dependence
Intervention: Device: Transcranial Magnetic Stimulation
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2010
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory

Conditions: Tick-Borne Encephalitis; Encephalitis, Tick-Borne; Tick-Borne Disease; Glycoprotein E, Flavivirus; NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2009
Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving

Condition: Cannabis Use
Intervention: Device: Repetitive Transcranial Magnetic Stimulation
Sponsor: National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified January 2010
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Conditions: Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsor: National Cancer Institute (NCI)
Recruiting - verified September 2009
Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)

Condition: Substance Use Disorders
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2009
Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality

Condition: Nicotine Dependence
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2009
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

Conditions: Cocaine Dependence; Cannabis Dependence; Schizophrenia
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2009
Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers

Condition: Nicotine Dependence
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2009
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
A Study for Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Condition: Multiple Sclerosis
Intervention: Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Sponsor: Bayer
Recruiting - verified March 2010
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Carboplatin; Drug: Pegfilgrastim
Sponsors: Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified March 2010
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: prednisone; Drug: vincristine sulfate; Drug: vinorelbine ditartrate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Preservative-Free Tafluprost (MK2452) for Open-Angle Glaucoma/Ocular Hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Preservative-Free MK2452 (Tafluprost); Drug: Comparator: timolol
Sponsor: Merck
Recruiting - verified March 2010
Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Relapsing Remitting Multiple Sclerosis

Conditions: Multiple Sclerosis; Vitamin D Deficiency
Interventions: Dietary Supplement: Cholecalciferol; Dietary Supplement: Cholecalciferol
Sponsor: Johns Hopkins University
Recruiting - verified March 2010
A Long Term Safety Study of MK4305 in Patients With Primary Insomnia

Condition: Insomnia
Interventions: Drug: MK4305; Drug: Comparator: Placebo to MK4305
Sponsor: Merck
Recruiting - verified March 2010
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1)

Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder

Conditions: Childhood Obsessive-Compulsive Disorder; Autism Spectrum Disorders
Intervention:
Sponsor: National Institute of Mental Health (NIMH)
Recruiting - verified November 2009
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development

Conditions: Drug Abuse; Prenatal Drug Exposure
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2009
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID)for Knee Pain Due to Osteoarthritis

Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified February 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By Chemotherapy With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Internal Monitoring of Eye Movement in Schizophrenia

Condition: Schizophrenia
Intervention:
Sponsor: National Eye Institute (NEI)
Recruiting - verified October 2009
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

Conditions: Herpesvirus; Adenovirus; Cytomegalovirus; Human Papillomavirus; Human Polyomavirus; Influenza Virus; Rhinovirus; Coronavirus; Respiratory Syncytial Virus
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

Condition: Healthy
Intervention: Biological: REGN668
Sponsors: Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2010
AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: MEK inhibitor AZD6244; Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System

Conditions: Back Pain; Chronic Low Back Pain; Internal Disc Disruption; Degenerative Disc Disease
Interventions: Biological: Biostat System; Drug: Sodium Chloride Injection
Sponsor: Spinal Restoration, Inc.
Recruiting - verified March 2010
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis

Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Early Intervention for Minority and Underserved Toddlers With Autism Spectrum Disorder (ASD)

Condition: Autism Spectrum Disorder
Interventions: Behavioral: Social Communication; Behavioral: Social communication
Sponsors: Johns Hopkins University; HRSA/Maternal and Child Health Bureau
Recruiting - verified November 2009
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/GW642444; Drug: Fluticasone propionate
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Condition: Myelodysplastic Syndromes
Interventions: Drug: decitabine; Drug: azacitidine
Sponsor: Eisai Inc.
Not yet recruiting - verified February 2010
Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
ACT-128800 in Relapsing-remitting Multiple Sclerosis

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800; Drug: Placebo
Sponsor: Actelion
Recruiting - verified February 2010
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

Condition: Leukemia
Intervention: Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization; Genetic: mutation analysis; Genetic: nucleic acid sequencing; Genetic: polymerase chain reaction; Genetic: western blotting; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Clinical Trial of the PfSPZ Vaccine

Condition: Plasmodium Falciparum
Intervention: Biological: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Sponsors: Sanaria Inc.; The PATH Malaria Vaccine Initiative (MVI)
Recruiting - verified March 2010
THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

Condition: Sickle Cell Disease
Interventions: Other: High Demand / Low Infusion; Other: PCA Dosing Plan
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: extended-release guanfacine hydrochloride; Drug: placebo; Drug: extended-release guanfacine hydrochloride
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

Condition: Posttraumatic Stress Disorder (PTSD)
Interventions: Drug: orvepitant; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

Condition: Influenza, Human
Intervention: Biological: VRC-FLUDNA056-00VP
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Novartis H1N1 Vaccine in Pregnant Women

Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

Condition: Influenza
Intervention: Biological: Inactivated Influenza H1N1 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

Condition: Chronic Obstructive Pulmonary Disease
Intervention: Device: ROX Anastomotic Coupler System (ACS)
Sponsor: ROX Medical, Inc.
Recruiting - verified March 2010
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: cetuximab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)

Condition: Typical Atrial Flutter
Intervention: Device: Therapy Cool Path Duo
Sponsor: St. Jude Medical
Recruiting - verified March 2010
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial

Conditions: Low Bone Mass; Low Bone Mineral Density; Males With Osteoporosis; Osteopenia; Osteoporosis
Interventions: Drug: 60 mg denosumab; Other: Placebo
Sponsor: Amgen
Recruiting - verified February 2010
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Oxycodone User Registry (OUR)

Condition: Pain
Intervention: Drug: oxycodone immediate release (OXYRX)
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
The Dual Antiplatelet Therapy Study (DAPT Study)

Condition: Coronary Artery Disease
Interventions: Drug: Placebo & Aspirin; Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors: Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Bristol-Myers Squibb; Sanofi-Synthelabo; Cordis Corporation; Eli Lilly and Company; Daiichi Sankyo Inc.; Medtronic
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil; Drug: Placebo
Sponsor: XenoPort, Inc.
Recruiting - verified March 2010
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550 + methotrexate; Drug: Placebo + Methotrexate
Sponsor: Pfizer
Recruiting - verified March 2010
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Phase I STEBVax in Healthy Adults

Condition: Staphylococcus Enterotoxin B
Intervention: Biological: STEBVax
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010
TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Conditions: Leukemia; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; MDS; Multiple Myeloma
Interventions: Drug: EPOCH-F/R; Drug: FLAG; Drug: Transplant Preparative Regimen (Flu/Cy/Mes); Drug: GVHD Prophylaxis (tacrolimus and sirolimus); Procedure: Double Cord Blood Transplantation
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
An Efficacy and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate, Non Steroidal Pain Medications and/or Corticosteroids

Condition: Arthritis, Rheumatoid
Interventions: Drug: placebo; Biological: golimumab; Biological: golimumab; Biological: golimumab
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Condition: Sciatica
Interventions: Drug: REGN475; Drug: REGN475; Drug: Placebo Injection
Sponsors: Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2010
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

Condition: Chronic Hepatitis C
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

Condition: Asthma
Interventions: Biological: MEDI-528; Biological: MEDI-528; Biological: MEDI-528; Other: Placebo
Sponsor: MedImmune LLC
Recruiting - verified March 2010
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study in Patients With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Condition: Paroxysmal Atrial Fibrillation
Interventions: Procedure: Atrial Fibrillation ablation procedure; Device: NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL
Sponsor: Biosense Webster, Inc.
Recruiting - verified February 2010
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia

Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: TOK-001; Drug: TOK-001; Drug: TOK-001
Sponsor: Tokai Pharmaceuticals
Recruiting - verified February 2010
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

Condition: Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis

Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
Sponsor: Shire Human Genetic Therapies, Inc.
Available - verified March 2010
Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx

Condition: Squamous Cell Carcinoma of Oropharynx
Interventions: Radiation: IMRT; Drug: Cisplatin; Drug: Carboplatin
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified March 2010
Social and Communication Outcomes for Young Children With Autism

Condition: Autism Spectrum Disorder
Intervention: Behavioral: Joint Attention Intervention
Sponsors: Health Resources and Services Administration (HRSA); University of California, Los Angeles; University of Washington; University of Michigan; Florida State University; Johns Hopkins University
Recruiting - verified November 2009
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Preventing Acute Chest Syndrome by Transfusion Feasibility Study

Conditions: Sickle Cell Disease; Secretory Phospholipase A2; sPLA2
Interventions: Biological: Single blood transfusion; Behavioral: Standard care
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3)

Conditions: HIV Infections; Hepatitis C; HCV Infection
Interventions: Drug: PEG2b plus ribavirin followed by placebo; Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Conditions: Renal Cell Carcinoma; Non-Hodgkin's Lymphoma
Intervention: Biological: MDX-1203
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage III or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of LY2189102 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes
Interventions: Drug: LY2189102; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
Sponsors: Regeneron Pharmaceuticals; Bayer
Recruiting - verified February 2010
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

Conditions: HIV; Asthma
Interventions: Drug: Darunavir; Drug: Ritonavir; Drug: Beclomethasone Dipropionate HFA
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified July 2009
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy Evaluation of Fx-1006A in Patients With V122I or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Condition: Amyloid Cardiomyopathy
Intervention: Drug: Fx-1006A
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

Conditions: Epilepsy; Epilepsy, Temporal Lobe; Depression; Depressive Disorder, Major
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Condition: Diabetes Mellitus, Type 2
Intervention: Drug: linagliptin QD for 7 days
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Model 4196 Left Ventricular (LV) Lead Chronic Performance Study

Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified March 2010
Abatacept Versus Adalimumab Head-to-Head

Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Nephropathy in Patients With Kidney Disease

Condition: Contrast Induced Nephropathy
Intervention: Drug: sodium bicarbonate
Sponsor: MD Scientific
Recruiting - verified February 2010
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Efficacy of Combination Therapies for Gonorrhea Treatment

Condition: Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Gentamicin; Drug: Gemifloxacin
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Condition: Osteoporosis, Post-Menopausal
Interventions: Drug: Teriparatide; Drug: Zoledronic Acid
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

Conditions: Small Cell Lung Carcinoma; Malignant Epithelial Neoplasms
Interventions: Drug: (Belinostat) (PDX101); Drug: Cisplatin; Drug: Etoposide
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Long Term Safety Study of Tanezumab in Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg; Biological: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

Conditions: Neuroblastoma; Sarcoma; Rhabdomyosarcoma-Embryonal; Rhabdomyosarcoma- Alveolar; Neuroectodermal Tumors, Primitive, Peripheral
Interventions: Drug: Tumor Purged/CD25 Depleted Lymphocytes; Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine; Drug: IL-4; Device: Miltenyi CliniMACS-System; Drug: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine; Drug: KLH; Drug: MAB 8H9; Drug: Endotoxin
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Conditions: Melanoma; Skin Cancer
Interventions: Drug: MART-1: 26-35(27L) Peptide; Drug: Montanide ISA 51 VG; Drug: gp100:154-162 Peptide; Drug: PG 13/Faf2aB C 162D1 (anti- MART-1 F5 TCR); Drug: PG13-154-Ecll AIB (anti-gp100:154-162 TCR); Procedure: Radiation; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Genetic: Anti-gp 100:154 TCR PBL; Genetic: Anti-MART-1 F5 TCR PBL
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Condition: Hairy Cell Leukemia
Intervention: Drug: BL22 (CAT-3888)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

Conditions: Head and Neck Neoplasms; Pheochromocytoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell
Intervention: Drug: Fostamatinib disodium (R9355788)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma

Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin; Drug: Bevacizumab
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Submission of Stem Cell Transplant Data to CIBMTR and NMDP

Conditions: Autologous Stem Cell Transplantation; Allogeneic Stem Cell Transplantation; Solid Tumors; Blood Cancers
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified November 2009
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: FDG-PET; Drug: Pemetrexed; Drug: Sirolimus
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Sunitinib to Treat Recurrent Brain Cancer

Conditions: Glioblastoma Multiforme; Malignant Gliomas; Anaplastic Gliomas
Intervention: Drug: Sutent (sunitinib)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis

Conditions: Familial Amyloid Polyneuropathy; ATTR-PN
Intervention: Drug: Fx-1006A
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Condition: Psoriasis
Intervention: Drug: CNTO 1959; Placebo
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Safety and Tolerability of STP206 in Healthy Adult Subjects

Condition: Healthy
Intervention: Drug: STP206 or vehicle control
Sponsor: Sigma Tau Pharmaceuticals, Inc.
Recruiting - verified March 2010
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: bendamustine as combination therapy with bortezomib
Sponsor: Cephalon
Recruiting - verified March 2010
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Placebo for Atrasentan 0,2 mg/mL solution; Drug: 0.25 mg Atrasentan QD; Drug: 0.75 mg Atrasentan QD; Drug: 1.75 mg Atrasentan QD
Sponsor: Abbott
Recruiting - verified January 2010
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified January 2010
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.

Condition: Advanced Solid Tumors
Intervention: Drug: Amrubicin
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Condition: Variola Major (Smallpox)
Interventions: Biological: IMVAMUNE® (liquid, intradermal); Biological: IMVAMUNE® (lyophilized); Biological: IMVAMUNE® (liquid, subcutaneous)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])

Conditions: Hereditary Angioedema; C1 Esterase Inhibitor Deficiency
Intervention: Biological: C1 inhibitor (human)
Sponsor: ViroPharma
Recruiting - verified August 2009
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Condition: Hereditary Angioedema
Interventions: Drug: Icatibant; Drug: Placebo
Sponsors: Jerini AG; Shire Human Genetic Therapies, Inc.
Recruiting - verified November 2009
A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3; Drug: liposomal doxorubicin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

Condition: Influenza
Interventions: Biological: A/Anhui/05; Biological: MF-59; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified December 2009
Primovist / Eovist in Renally Impaired Patients

Condition: Contrast Media
Intervention: Drug: Eovist (Primovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified March 2010
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)

Conditions: Myelogenous Leukemia, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Myelogenous Leukemia, Chronic, Aggressive Phase
Interventions: Drug: SCH 900776; Drug: Cytarabine
Sponsor: Schering-Plough
Recruiting - verified March 2010
Effect of LY2062430 on the Progression of Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training

Conditions: Movement Disorders; Heathly Subjects
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery

Conditions: Atrial Fibrillation; Mitral Valve Insufficiency; Mitral Valve Stenosis
Interventions: Procedure: Mitral valve surgery with ligation/excision of left atrial appendage with ablation; Procedure: Mitral valve surgery with ligation/excision of left atrial appendage
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2010
Ventavis® Registry Protocol

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
Sponsor: Actelion
Recruiting - verified March 2010
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Detector Computed Tomography

Conditions: Arterial Occlusive Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia; Vascular Diseases; Arteriosclerosis; Ischemia; Coronary Artery Disease
Intervention: Procedure: 320 Volume Detector Computed Tomography
Sponsors: Johns Hopkins University; Toshiba America Medical Systems, Inc.
Recruiting - verified November 2009
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

Condition: Lung Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Fentanyl in Patients With Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fentanyl citrate; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Other: laboratory biomarker analysis
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Adaptation Among Adolescents and Adults With Klinefelter Syndrome

Condition: Klinefelter Syndrome
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2010
Open Label Study of Sipuleucel-T

Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

Conditions: Lymphohistiocytosis, Hemophagocytic; Common Variable Immunodeficiency; Severe Combined Immunodeficiency
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Conditions: Acute Ischemic Stroke; Stroke; Brain Infarction
Interventions: Drug: Eptifibatide; Drug: rt-PA
Sponsors: University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome

Condition: Rett Syndrome
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified April 2009
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Intervention: Drug: Bendamustine in combination with Rituximab
Sponsor: Cephalon
Recruiting - verified March 2010
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Conditions: Anaphylaxis; Hypotension; Bronchospasm; Angioedema
Interventions: Drug: Epinephrine; Procedure: Bone Marrow Apsiration; Drug: Omalizumab (Xolair)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel(Registered Trademark)+CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

Condition: Malaria
Intervention: Drug: BSAM2/Alhydrogel + CPG 7909
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2009
The Nosology and Etiology of Leukodystrophies of Unknown Causes

Conditions: Leukodystrophy; Leukoencephalopathy
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2010
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Fatigue in Healthy Individuals

Conditions: Healthy Volunteer; Fatigue; Depression
Intervention:
Sponsor: National Institute of Nursing Research (NINR)
Recruiting - verified February 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Pathogenesis of Physical Induced Urticarial Syndromes

Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Randomized Withdrawal Study of Desvenlafaxine Succinate Sustained Release in Outpatients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Exelixis
Recruiting - verified December 2009
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

Condition: Depression
Interventions: Other: Placebo; Drug: orvepitant
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition: Myocardial Infarction
Interventions: Drug: Prochymal®; Drug: Placebo
Sponsor: Osiris Therapeutics
Recruiting - verified March 2010
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Condition: Euvolemic Hyponatremia
Interventions: Drug: Lixivaptan; Drug: Placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
A Study of Tanezumab in Adults With Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Exploring a Motor Learning Technique Based on the Mirror Motor Neuron System

Condition: Healthy
Intervention:
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Model 4195 Left Ventricular (LV) Lead Chronic Performance Study

Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Conditions: Bipolar; Depression
Interventions: Drug: lurasidone; Drug: lurasidone; Drug: Placebo
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Condition: Bipolar Depression
Interventions: Drug: lurasidone + (lithium or divalproex); Drug: Placebo + (lithium or divalproex)
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Condition: Bipolar I, Depression
Intervention: Drug: lurasidone
Sponsor: Dainippon Sumitomo Pharma America
Recruiting - verified February 2010
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-263; Drug: FCR; Drug: BR
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (Study P05522)

Condition: Primary Hypercholesterolemia
Interventions: Drug: ezetimibe; Drug: Placebo
Sponsors: Schering-Plough; Merck
Recruiting - verified March 2010
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Procedure: adjuvant therapy
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates

Conditions: Cocaine Addiction; Cocaine Abuse
Intervention:
Sponsor: National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified January 2010
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Condition: Epilepsy With Simple or Complex Partial Onset Seizures
Interventions: Drug: Eslicarbazepine acetate; Drug: Eslicarbazepine acetate
Sponsor: Sepracor, Inc.
Recruiting - verified March 2010
Chemotherapy or Observation in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate; Procedure: standard follow-up care
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Combination Pain Therapy in HIV Neuropathy

Conditions: HIV Infections; Peripheral Neuropathy
Interventions: Drug: Duloxetine; Drug: Duloxetine placebo; Drug: Methadone; Drug: Methadone placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Tanezumab in Osteoarthritis of the Hip or Knee (2)

Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Condition: Diabetes Mellitus Type II Non Insulin Dependent
Interventions: Dietary Supplement: Vitamin E; Dietary Supplement: Vitamin C; Dietary Supplement: Lipid Oxidation
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2010
Concentration and Activity of Lapatinib in Vestibular Schwannomas

Conditions: Vestibular Schwannoma; NF2; Neurofibromatosis 2; Acoustic Neuroma; Auditory Tumor
Intervention: Drug: lapatinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Children's Tumor Foundation; GlaxoSmithKline; New York University; Ohio State University; House Ear Institute
Recruiting - verified February 2010
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Ezetimibe/Simvastatin (MK0653A) vs Rosuvastatin vs Doubling Statin Dose in Patients With Cardiovascular Disease and Diabetes Mellitus

Conditions: Cardiovascular Disorder; Diabetes Mellitus
Interventions: Drug: ezetimibe (+) simvastatin; Drug: Comparator: simvastatin 40 mg or atorvastatin 20 mg; Drug: Comparator: rosuvastatin; Drug: Comparator: atorvastatin 10 mg or simvastatin 20 mg
Sponsor: Merck
Recruiting - verified March 2010
Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD).

Condition: Gastroesophageal Reflux
Intervention: Drug: Rabeprazole sodium
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eisai Inc.
Recruiting - verified February 2010
An Observational Study of Fungal Biomarkers

Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy

Conditions: Cancer; Fatigue
Intervention:
Sponsor: National Institute of Nursing Research (NINR)
Recruiting - verified December 2009
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Conditions: HIV Infections; Treatment Naive
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

Condition: Psoriasis
Interventions: Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 intravenous infusion; Drug: AbGn168 subcutaneous injection
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of TAK-491 Combined With Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Chlorthalidone; Drug: Chlorthalidone; Drug: TAK-491; Drug: TAK-491; Drug: TAK-491
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Conditions: Gastroparesis; Diabetic Gastroparesis; Diabetes; Diabetes Mellitus; Delayed Gastric Emptying
Interventions: Drug: metoclopramide; Drug: Placebo
Sponsor: Evoke Pharma
Recruiting - verified March 2010
Open-Label Study of Oral Treprostinil in Digital Ulcers

Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Efficacy and Safety of Azilsartan Plus Chlorthalidone in Subjects With Moderate to Severe Hypertension

Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: LY451395; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Study of of MORAb-004 in Subjects With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: MORAb-004 (monoclonal antibody to TEM1)
Sponsor: Morphotek
Recruiting - verified March 2010
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
NicVAX/Placebo as an Aid for Smoking Cessation

Conditions: Smoking Cessation; Smoking; Tobacco Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo vaccine
Sponsors: Nabi Biopharmaceuticals; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified February 2010
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Longitudinal Study of the Human Intestinal Microbiome

Condition: Intestinal Microbiome
Intervention: Drug: Ciprofloxacin hydrochloride
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2009
Phase III Acute Coronary Syndrome

Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Observational Study of Cholesterol in Coronary Arteries

Conditions: Myocardial Infarction; Angina; Coronary Artery Disease; Myocardial Ischemia
Intervention: Device: Intravascular Near Infrared Spectroscopy
Sponsor: InfraReDx
Recruiting - verified February 2010
Tanezumab In Osteoarthritis Of The Knee (2)

Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Atorvastatin Three Year Pediatric Study

Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
Sponsor: Pfizer
Recruiting - verified March 2010
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Post-Market Study of the 3DKnee™ System

Conditions: Degenerative Joint Disease; Osteoarthritis; Rheumatoid Arthritis; Traumatic Arthritis
Intervention: Device: 3DKnee™ System
Sponsor: Encore Medical, L.P.
Recruiting - verified March 2010
A Study of Ridaforolimus in Non-Small Cell Lung Cancer Patients With KRAS Mutations

Condition: Non-small Cell Lung Cancer
Interventions: Drug: deforolimus; Drug: Comparator: Blinded Ridaforolimus; Drug: Comparator: Blinded Placebo
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
PF-00299804 As A Single Oral Agent In Untreated Adenocarcinoma Of The Lung In Non-Smokers Or Former Light Smokers

Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

Condition: Ischemia
Interventions: Other: BMS747158; Other: BMS747158
Sponsor: Lantheus Medical Imaging
Recruiting - verified March 2010
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3

Conditions: Thyroid Disease; Healthy
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Raltegravir; Drug: Darunavir; Drug: Ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Bristol-Myers Squibb; Gilead Sciences; Merck; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Recruiting - verified June 2009
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy

Conditions: Leukemia; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ABT-888; Drug: cyclophosphamide; Other: immunologic technique; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Extension Study Of Tanezumab In Osteoarthritis

Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified March 2010
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome.

Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease
Interventions: Procedure: Mitral Valve Repair with Annuloplasty; Procedure: Mitral Valve Replacement
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation

Conditions: Mitral Valve Insufficiency; Coronary Artery Disease
Interventions: Procedure: Mitral Valve Repair; Procedure: CABG
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: CS7017 tablets; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Study of NNZ-2566 in Patients With Traumatic Brain Injury

Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsor: Neuren Pharmaceuticals Limited
Not yet recruiting - verified March 2010
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Study of Ataluren (PTC124™) in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified January 2010
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; ETRA; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Recruiting - verified March 2010
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: alvocidib; Drug: cytarabine; Drug: mitoxantrone hydrochloride
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
SR-PAAS - Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil

Conditions: PAH; Pulmonary Arterial Hypertension; Pulmonary Hypertension; Sitaxsentan; ETRA
Interventions: Drug: Sitaxsentan; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Open-label Study Providing Monotherapy (Sitaxsentan) and Combination Therapy (Sitaxsentan+Sildenafil) to Subjects With PAH to Assess Long-term Safety

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH
Interventions: Drug: Sitaxsentan; Drug: Sitaxsentan and Sildenafil
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors

Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Condition: Tularemia
Intervention: Biological: Live Francisella Tularensis Vaccine
Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting - verified February 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients

Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233AM1)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Phase II Study of Digitoxin to Treat Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: digitoxin; Drug: digitoxin; Other: placebo
Sponsors: Johns Hopkins University; FDA Office of Orphan Products Development
Not yet recruiting - verified March 2010
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.

Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Condition: Carcinoid Syndrome
Interventions: Drug: lanreotide; Drug: placebo
Sponsors: Tercica; Ipsen
Recruiting - verified March 2010
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care

Condition: Asthma
Interventions: Drug: tiotropium 5mcg/day; Drug: tiotropium 5mcg/day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohns Disease Who Have Been Previously Treated With Anti-TNF Therapy

Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Conditions: NOMID; CINCA Syndrome
Interventions: Drug: Canakinumab; Drug: ACZ885
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified September 2009
An Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234AM2)

Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Neuropsychological Measures in Patients Undergoing Radiation Therapy for Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2008
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma

Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant

Conditions: Distress; Hematopoietic Stem Cell Transplantation
Intervention: Behavioral: Problem Solving Education
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified August 2009
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Condition: Scleroderma
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Exercise and Inflammation in the Elderly

Conditions: Inflammation; Insulin Sensitivity
Interventions: Other: Weight Loss; Other: Aerobic Exercise Training
Sponsor: Department of Veterans Affairs
Recruiting - verified February 2010
A Placebo-Controlled Study of AZD0530 in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: rhGAD65; Drug: rhGAD65; Drug: Placebo
Sponsor: Diamyd Therapeutics AB
Recruiting - verified March 2010
Tanezumab in Osteoarthritis Of The Hip

Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Malaria Challenge With NF54 Strain

Condition: Plasmodium Falciparum Malaria
Intervention: Other: NF54 P. falciparum isolate
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
An Efficacy Study of MORAb-009 in Subjects With Pleural Mesothelioma

Condition: Malignant Pleural Mesothelioma
Intervention: Drug: MORAb-009 by IV on Days 1 and 8 every 21 days for 6 cycles.
Sponsor: Morphotek
Recruiting - verified March 2010
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Follow-Up Study for Exubera

Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

Condition: Major Depressive Disorder (MDD)
Intervention: Drug: repeat dose
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects
Interventions: Drug: temozolomide; Drug: vorinostat; Procedure: adjuvant therapy; Procedure: cognitive assessment; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2010
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)

Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Cephalexin; Drug: Trimethoprim-sulfamethoxazole (TS); Drug: Clindamycin; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2009
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Malignant Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors

Conditions: Renal Cell Carcinoma; Non-small Cell Lung Cancer; Malignant Melanoma; Epithelial Ovarian Cancer; Colorectal Adenocarcinoma
Intervention: Biological: MDX-1105
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Fibromyalgia Health Outcome Study on Cost of Treatments

Condition: Fibromyalgia
Intervention: Drug: Treatment for Fibromyalgia
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Phase 1 Dose Escalation Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

Condition: Age-Related Macular Degeneration
Intervention: Drug: PF-04523655
Sponsors: Pfizer; Quark Pharmaceuticals
Recruiting - verified March 2010
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: Ixabepilone + Carboplatin; Drug: Paclitaxel + Carboplatin
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)

Conditions: Osteoarthritis; Avascular Necrosis; Rheumatoid Arthritis
Intervention: Device: Cormet Hip Resurfacing
Sponsor: Corin
Recruiting - verified February 2010
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Conditions: Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer
Interventions: Drug: Capecitabine; Drug: Epirubicin; Drug: AMG 102; Drug: Cisplatin
Sponsor: Amgen
Recruiting - verified March 2010
A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Condition: Rheumatoid Arthritis
Intervention: Drug: CNTO 136
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

Condition: Hepatitis C, Chronic
Interventions: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2009
Computer-Assisted Self-Administration of Ethanol

Condition: Alcoholic Intoxication
Interventions: Drug: Alcohol; Procedure: Self-Administration
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified May 2009
Oral Nifedipine to Treat Iron Overload

Conditions: Thalassemia; Iron Overload; Hemochromatosis
Interventions: Drug: Nifedipine; Procedure: Phlebotomy; Procedure: Urinalysis; Procedure: Echocardiogram; Procedure: Electrocardiogram
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2009
Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)

Conditions: Early Pancreatic Neoplasia; Familial Pancreatic Neoplasia
Intervention:
Sponsors: Sidney Kimmel Comprehensive Cancer Center; V Foundation for Cancer Research
Recruiting - verified March 2010
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Condition: Huntington's Disease
Interventions: Drug: Creatine Monohydrate (HD-02); Drug: placebo
Sponsors: Massachusetts General Hospital; University of Rochester; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsor: Agennix
Recruiting - verified March 2010
Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

Condition: Obesity
Interventions: Drug: Sincalide; Drug: Ursodiol Acid; Procedure: High Fat/Low Fat Diet
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Evaluation of a Medical Food for Chronic Wounds

Condition: Foot Ulcer, Diabetic
Interventions: Other: Medical Food; Other: Drink mix calorically similar to experimental product
Sponsor: Abbott Nutrition
Recruiting - verified March 2010
Efficacy Study of XL184 in Adults With Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Response to Standard HIV Treatment in Bamako, Mali

Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Imatinib Mesylate in Treating Patients With Sclerodermatous Chronic Graft-Versus-Host Disease

Condition: Cancer
Interventions: Drug: imatinib mesylate; Genetic: reverse transcriptase-polymerase chain reaction; Other: confocal microscopy; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: biopsy
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna

Condition: Aortic Valve Disease
Interventions: Device: Mitroflow Aortic Pericardial Heart Valve (CarboMedics); Device: Carpentier-Edwards Magna Tissue Valve
Sponsor: Sorin Group USA, Inc.
Recruiting - verified March 2010
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

Conditions: Diabetic Retinopathy; Diabetes Complications
Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low
Sponsor: Pfizer
Recruiting - verified March 2010
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sunitinib malate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2010
Varenicline to Reduce Alcohol Consumption in Heavy Drinkers

Condition: Alcohol Drinking
Interventions: Drug: Varenicline; Drug: Varenicline (Chantix)
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2010
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Investigating Superion™ In Spinal Stenosis [ISISS]

Conditions: Lumbar Spinal Stenosis; Neurogenic Intermittent Claudication
Interventions: Device: Superion™ Interspinous Spacer; Device: X-STOP® IPD® Device
Sponsor: VertiFlex, Incorporated
Recruiting - verified February 2010
Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3

Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Condition: Macular Telangiectasia
Intervention: Drug: Ranibizumab
Sponsor: National Eye Institute (NEI)
Recruiting - verified January 2010
Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Aerobic Exercise in Patients With Pulmonary Hypertension

Condition: Hypertension, Pulmonary
Interventions: Procedure: Excerise Training; Procedure: Patient Education (Placebo)
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified April 2009
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)

Conditions: Schizophrenia; Psychotic Disorders
Interventions: Behavioral: Patient-centered computerized tool; Behavioral: Written educational materials
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

Conditions: Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: JNJ-26481585.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Pazopanib in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

Conditions: Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
EZN-2285 or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Pain; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: acupressure therapy; Procedure: biopsy; Procedure: bone marrow aspiration; Procedure: pain therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
CEP-701 (Lestaurtinib) in Myelofibrosis

Conditions: Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention: Drug: CEP-701 (Lestaurtinib)
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Research Tissue Bank

Conditions: Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Laboratory-Treated Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, and Fludarabine in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: aldesleukin
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

Conditions: Atherosclerosis; Diabetes Mellitus; Obesity; Dyslipidemia; Hypertension
Interventions: Behavioral: Exercise; Behavioral: Weight Loss
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2010
Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Conditions: Myeloproliferative Disease; Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera
Intervention:
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402

Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Hepatitis C Treatment and Atherosclerosis

Conditions: Chronic Hepatitis C; Atherosclerosis
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2009
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Conditions: Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
Intervention: Drug: CAT-8015
Sponsors: MedImmune LLC; National Cancer Institute (NCI)
Recruiting - verified March 2010
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Montelukast in Treating Patients With Bronchiolitis Obliterans After Stem Cell Transplant

Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Dose Escalation and Remission (DEAR)

Condition: Ulcerative Colitis
Intervention: Drug: mesalamine
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Shire Pharmaceutical Development
Recruiting - verified February 2010
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: midostaurin; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Conditions: Solid Tumor Malignancy; Lymphoid Malignancy (Lymphoma and CLL); Leukemia; Lymphoma
Intervention: Drug: SNX-5422 Mesylate Hsp90 inhibitor
Sponsors: Pfizer; National Cancer Institute (NCI)
Recruiting - verified March 2010
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

Conditions: Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Hsp90 inhibitor SNX-5422 mesylate; Other: flow cytometry; Other: high performance liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Condition: Chronic Angina
Intervention: Drug: Ranolazine
Sponsor: Gilead Sciences
Recruiting - verified February 2010
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Condition: Chronic Myelogenous Leukemia - Chronic Phase
Intervention: Drug: Nilotinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified March 2010
Eating Behavior in Adolescents

Conditions: Overweight; Eating Behavior; Binge Eating
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2009
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146AM4)

Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Large Cell; Carcinoma, Squamous Cell
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: inhaled mannitol; Drug: Placebo comparator
Sponsors: Pharmaxis; ethica Clinical Research Inc.
Recruiting - verified March 2010
Transthyretin-Associated Amyloidoses Outcomes Survey (THAOS)

Condition: TTR-associated Amyloidosis
Intervention: Other: THAOS is a noninterventional patient registry
Sponsor: FoldRx Pharmaceuticals
Recruiting - verified February 2010
Defibrotide for Patients With Hepatic VOD: A Treatment IND Study

Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: aflibercept
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effects of Smoking on Opioid Receptor Binding: A PET Study

Condition: Substance-related Discorder
Interventions: Drug: Nicotine; Drug: Carfentanil
Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2009
Cyclophosphamide and Fludarabine Followed By Autologous Gene-Modified Lymphocytes, Vaccine Therapy, and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: ALVAC-CEA vaccine; Biological: aldesleukin; Biological: autologous anti-gp100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified October 2008
Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ambrisentan plus sildenafil or tadalafil
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Condition: Head and Neck Cancer
Interventions: Biological: IMC-A12; Biological: cetuximab
Sponsor: ImClone LLC
Recruiting - verified March 2010
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Emphysema; Bronchitis, Chronic
Intervention:
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2009
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group
Recruiting - verified March 2010
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: etoposide; Drug: tipifarnib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720AM3)

Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Conditions: HIV Infections; Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent human papillomavirus vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified June 2009
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures

Condition: Epilepsy
Intervention: Drug: pregabalin
Sponsor: Pfizer
Recruiting - verified March 2010
Age-Related Eye Disease Study (AREDS) Follow-Up

Conditions: Age-Related Macular Degeneration; Cataract
Intervention:
Sponsor: National Eye Institute (NEI)
Recruiting - verified December 2009
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
The Study of Barrett's Esophagus: What Are the Factors of Progression

Conditions: Barrett's Esophagus; Esophageal Neoplasms
Intervention:
Sponsors: Kansas City Veteran Affairs Medical Center; TAP Pharmaceutical Products Inc.
Recruiting - verified February 2010
A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia

Condition: Hairy Cell Leukemia
Intervention: Biological: CAT 8015
Sponsors: MedImmune LLC; Cambridge Antibody Technology
Recruiting - verified March 2010
A Study of the Safety and Effectiveness of Doripenem Compared With Imipenem in the Treatment of Patients With Ventilator-associated Pneumonia

Conditions: Pneumonia; Pneumonia, Bacterial
Interventions: Drug: doripenem; Drug: imipenem/cilastatin
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer

Condition: Breast Tumors
Intervention: Drug: Trabectedin; ET 743; Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar S.A.
Recruiting - verified February 2010
ABT-888 and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: ABT-888; Drug: carboplatin; Drug: topotecan hydrochloride; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine

Condition: Venezuelan Equine Encephalomyelitis
Intervention: Biological: VEE TC-83
Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2010
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine

Condition: Eastern Equine Encephalitis
Intervention: Biological: Inactivated, Dried, TSI-GSD 104, EEE
Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2010
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83

Condition: Venezuelan Equine Encephalomyelitis
Intervention: Biological: VEE C-84
Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2010
GAUSS: A Study of RO5072759 in Patients With Indolent Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Condition: Myelofibrosis
Intervention: Drug: Fludarabine, Melphalan +/- ATG
Sponsor: Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010
Trial of Enzastaurin and Bevacizumab in Adults With Recurrent Malignant Gliomas

Condition: Recurrent Glioblastoma
Interventions: Drug: enzastaurin; Drug: bevacizumab
Sponsors: Eli Lilly and Company; Genentech
Recruiting - verified March 2010
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA)

Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel; Drug: pertuzumab; Drug: placebo; Drug: trastuzumab
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified March 2010
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

Condition: Osteoarthritis
Interventions: Drug: SD-6010; Drug: SD-6010; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Conditions: Colorectal Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate 150 mg BID; Drug: matching placebo BID
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

Condition: Inflammatory Disorder
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Studying Patients With a Personal or Family History of Cancer Caused by a Virus

Conditions: Lymphoma; Lymphoproliferative Disorder; Sarcoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: biologic sample preservation procedure; Other: cytology specimen collection procedure; Other: immunologic technique; Procedure: biopsy; Procedure: study of high risk factors
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2009
An Investigational Drug, PD 0332991, Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsor: Pfizer
Recruiting - verified March 2010
VA NEPHRON-D: Diabetes iN Nephropathy Study

Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Condition: Lymphoma
Interventions: Drug: bortezomib; Drug: lenalidomide
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Pertuzumab and Cetuximab in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Cetuximab

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified December 2008
A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Lapatinib; Drug: Trastuzumab; Drug: Endocrine
Sponsors: Baylor Breast Care Center; GlaxoSmithKline
Recruiting - verified February 2010
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: PF-00299804; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections
Interventions: Drug: Enfuvirtide; Drug: Raltegravir; Drug: Darunavir; Drug: Tipranavir; Drug: Etravirine; Drug: Maraviroc
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group
Recruiting - verified April 2009
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Condition: Cancer
Interventions: Drug: TAK-285 Dose Escalation Cohorts; Drug: TAK-285 Recommended Phase 2 Dosing Cohort
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER) (Study P04736AM2)

Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

Condition: Epilepsies, Partial
Interventions: Drug: pregabalin 600 mg/day; Drug: pregabalin 150 mg/day
Sponsor: Pfizer
Recruiting - verified March 2010
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Find Paid Clinical Trials in Maryland - Clinical Trials

Find Paid Clinical Trials in Maryland

Paid Clinical Trials and Focus Groups by Location